Smith & Nephew reported Q2 underlying revenue growth of 1.6%, trailing management expectations. Strength in Sports Medicine and ENT was offset by weakness in U.S. Orthopaedics and Advanced Wound Bioactives, suggesting uneven demand across segments.
Smith & Nephew reported Q2 underlying revenue growth of 1.6%, trailing management expectations. Strength in Sports Medicine and ENT was offset by weakness in U.S. Orthopaedics and Advanced Wound Bioactives, suggesting uneven demand across segments.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
